Insider Transactions in Q4 2025 at Roivant Sciences Ltd. (ROIV)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 20
2025
|
Ilan Oren |
SELL
Payment of exercise price or tax liability
|
Direct |
281
-0.24%
|
$4,777
$17.74 P/Share
|
|
Oct 20
2025
|
Ilan Oren |
BUY
Grant, award, or other acquisition
|
Direct |
1,507
+1.25%
|
-
|
|
Oct 20
2025
|
James C Momtazee |
SELL
Payment of exercise price or tax liability
|
Direct |
158
-0.15%
|
$2,686
$17.74 P/Share
|
|
Oct 20
2025
|
James C Momtazee |
BUY
Grant, award, or other acquisition
|
Direct |
789
+0.72%
|
-
|
|
Oct 20
2025
|
Epperly Melissa B, |
BUY
Grant, award, or other acquisition
|
Direct |
1,056
+1.82%
|
-
|
|
Oct 17
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
118,418
-7.29%
|
$2,013,106
$17.06 P/Share
|
|
Oct 17
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
118,418
+6.8%
|
$1,776,270
$15.85 P/Share
|
|
Oct 16
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
318,282
-17.46%
|
$5,410,794
$17.05 P/Share
|
|
Oct 16
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
318,282
+14.86%
|
$4,774,230
$15.85 P/Share
|
|
Oct 15
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
414,683
-21.6%
|
$6,634,928
$16.93 P/Share
|
|
Oct 15
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
414,683
+17.76%
|
$6,220,245
$15.85 P/Share
|
|
Oct 13
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
20,727
-1.36%
|
$331,632
$16.25 P/Share
|
|
Oct 13
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,727
+1.34%
|
$310,905
$15.85 P/Share
|
|
Oct 09
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
104,940
-6.52%
|
$1,679,040
$16.3 P/Share
|
|
Oct 09
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
104,940
+6.12%
|
$1,574,100
$15.85 P/Share
|
|
Oct 08
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
138,602
-8.43%
|
$2,217,632
$16.2 P/Share
|
|
Oct 08
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
138,602
+3.96%
|
$1,524,622
$11.65 P/Share
|
|
Oct 07
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
355,161
-19.09%
|
$5,682,576
$16.15 P/Share
|
|
Oct 07
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
355,161
+6.32%
|
$3,196,449
$9.05 P/Share
|
|
Oct 06
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
171,396
-10.22%
|
$2,742,336
$16.34 P/Share
|
|
Oct 06
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
171,396
+3.28%
|
$1,542,564
$9.05 P/Share
|